Tag: T-Cell lymphoma

Prescient Therapeutics gets FDA orphan drug status for PTX-100 in PTCL

pallavi123- July 15, 2022

Prescient Therapeutics has secured the orphan drug designation for its PTX-100 compound from the US Food and Drug Administration (FDA) for the treatment of peripheral ... Read More

Pfizer to acquire immuno-oncology company Trillium Therapeutics for $2.2bn

pallavi123- August 27, 2021

US pharma giant Pfizer has agreed to acquire Trillium Therapeutics, a publicly listed Canadian clinical stage immuno-oncology company, for $18.5 per share or $2.26 billion ... Read More

Bioniz Therapeutics gets EC orphan drug status for BNZ-1 for CTCL

pallavi123- April 6, 2021

Bioniz Therapeutics has secured orphan drug designation for BNZ-1 from the European Commission (EC) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare type ... Read More

Bioniz Therapeutics announces positive data from BNZ-1 phase 1/2 trial in rCTCL

pharmanewsdaily- December 6, 2020

Bioniz Therapeutics has announced positive data from a phase 1/2 clinical trial of BNZ-1 for the treatment of relapsed or refractory cutaneous T-cell lymphoma (rCTCL). ... Read More

Takeda gets extended EC approval for ADCETRIS in sALCL

pharmanewsdaily- May 17, 2020

Takeda Pharmaceutical has secured extended approval for ADCETRIS (brentuximab vedotin) in the European Union to include the treatment of previously untreated systemic anaplastic large cell ... Read More

Soligenix all set to begin FLASH clinical trial for SGX301 in CTCL

pharmanewsdaily- December 4, 2019

US biopharma company Soligenix has wrapped up enrolling patients for its phase 3 Fluorescent Light Activated Synthetic Hypericin clinical trial (FLASH clinical trial) for SGX301 ... Read More

Verastem gets FDA orphan drug status for COPIKTRA for T-Cell lymphoma

pharmanewsdaily- October 7, 2019

Verastem Oncology has secured orphan drug designation for COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K), from the US Food and Drug Administration (FDA) ... Read More